請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/637
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙 | |
dc.contributor.author | Shu-Fan Kuo | en |
dc.contributor.author | 郭書帆 | zh_TW |
dc.date.accessioned | 2021-05-11T04:50:25Z | - |
dc.date.available | 2019-08-27 | |
dc.date.available | 2021-05-11T04:50:25Z | - |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-15 | |
dc.identifier.citation | 1. Egan BM, Li J, Hutchison FN, Ferdinand KC: Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation 2014;130:1692-9.
2. 衛生福利部國民健康署: statistical yearbook of health promotion 2016. 2018. 3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. 4. Thomopoulos C, Parati G, Zanchetti A: Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014;32:2285-95. 5. Rapsomaniki E, Timmis A, George J, et al.: Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899-911. 6. Hörnsten C, Weidung B, Littbrand H, et al.: High blood pressure as a risk factor for incident stroke among very old people: a population-based cohort study. Journal of hypertension 2016;34:2059-65. 7. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y: Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005;36:1859-63. 8. Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52. 9. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT: Incidence of hypertension and risk of cardiovascular events among ethnic Chinese: report from a community-based cohort study in Taiwan. J Hypertens 2007;25:1355-61. 10. Hedayati SS, Elsayed EF, Reilly RF: Non-pharmacological aspects of blood pressure management: what are the data? Kidney Int 2011;79:1061-70. 11. Tseng CD, Yen AM, Chiu SY, Chen LS, Chen HH, Chang SH: A predictive model for risk of prehypertension and hypertension and expected benefit after population-based life-style modification (KCIS No. 24). Am J Hypertens 2012;25:171-9. 12. Ishikawa Y, Ishikawa J, Ishikawa S, et al.: Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School Cohort Study. Hypertens Res 2008;31:1323-30. 13. Chiu YH, Wu SC, Tseng CD, Yen MF, Chen TH: Progression of pre-hypertension, stage 1 and 2 hypertension (JNC 7): a population-based study in Keelung, Taiwan (Keelung Community-based Integrated Screening No. 9). J Hypertens 2006;24:821-8. 14. Yen AM, Chen TH: Kinetic epidemiological model for elucidating sexual difference of hypertension (KCIS no.20). J Eval Clin Pract 2011;17:130-5. 15. Ferrannini E, Cushman WC: Diabetes and hypertension: the bad companions. The Lancet 2012;380:601-10. 16. Mazzali M, Kanbay M, Segal MS, et al.: Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010;12:108-17. 17. Huang C, Zhan J, Liu YJ, Li DJ, Wang SQ, He QQ: Association between alcohol consumption and risk of cardiovascular disease and all-cause mortality in patients with hypertension: a meta-analysis of prospective cohort studies. Mayo Clin Proc 2014;89:1201-10. 18. Husain K, Ansari RA, Ferder L: Alcohol-induced hypertension: Mechanism and prevention. World journal of cardiology 2014;6:245-52. 19. Tseng CH: Betel nut chewing is associated with hypertension in Taiwanese type 2 diabetic patients. Hypertens Res 2008;31:417-23. 20. Lee H-Y, Hwang J-S, Jeng J-S, Wang J-D: Quality-Adjusted Life Expectancy (QALE) and Loss of QALE for Patients With Ischemic Stroke and Intracerebral Hemorrhage. Stroke 2010;41:739-44. 21. Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM: Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology 2013;81:1588-95. 22. Banks JL, Marotta CA: Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091-6. 23. Patel N, Rao VA, Heilman-Espinoza ER, Lai R, Quesada RA, Flint AC: Simple and reliable determination of the modified rankin scale score in neurosurgical and neurological patients: the mRS-9Q. Neurosurgery 2012;71:971-5; discussion 5. 24. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R: Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making 2010;30:341-54. 25. Dijkland Simone A, Voormolen Daphne C, Venema E, et al.: Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials. Stroke 2018;49:965-71. 26. Broderick JP, Adeoye O, Elm J: Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke 2017;48:2007-12. 27. Hong KS, Saver JL: Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke 2009;40:3828-33. 28. Ali M, MacIsaac R, Quinn TJ, et al.: Dependency and health utilities in stroke: Data to inform cost-effectiveness analyses. European stroke journal 2017;2:70-6. 29. Pan SL, Lien IN, Yen MF, Lee TK, Chen TH: Dynamic aspect of functional recovery after stroke using a multistate model. Arch Phys Med Rehabil 2008;89:1054-60. 30. Pan SL, Chen HH: Time-varying Markov regression random-effect model with Bayesian estimation procedures: Application to dynamics of functional recovery in patients with stroke. Math Biosci 2010;227:72-9. 31. Jahromi AS, Cina CS, Liu Y, Clase CM: Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. J Vasc Surg 2005;41:962-72. 32. de Weerd M, Greving JP, Hedblad B, et al.: Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010;41:1294-7. 33. de Weerd M, Greving Jacoba P, de Jong Anne WF, Buskens E, Bots Michiel L: Prevalence of Asymptomatic Carotid Artery Stenosis According to Age and Sex. Stroke 2009;40:1105-13. 34. Halliday A, Harrison M, Hayter E, et al.: 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010;376:1074-84. 35. Mantese Vito A, Timaran Carlos H, Chiu D, Begg Richard J, Brott Thomas G: The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke 2010;41:S31-S4. 36. Chen T, Yu D, Cornelius V, et al.: Potential health impact and cost-effectiveness of drug therapy for prehypertension. Int J Cardiol 2017;240:403-8. 37. Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. New England Journal of Medicine 2006;354:1685-97. 38. Whelton PK, Carey RM, Aronow WS, et al.: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269-324. 39. LeFevre ML: Screening for asymptomatic carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:356-62. 40. Hsieh CY, Wu DP, Sung SF: Trends in vascular risk factors, stroke performance measures, and outcomes in patients with first-ever ischemic stroke in Taiwan between 2000 and 2012. J Neurol Sci 2017;378:80-4. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/handle/123456789/637 | - |
dc.description.abstract | <研究背景> 雖然控制高血壓已廣被接受為預防中風之必要措施,但不同階段的血壓控制對於發生中風所造成之影響不同,使得對於不同高血壓防治方法之實證效益難以進行評估。此外,近年來對於運用初段預防進行高血壓防治受到重視,然而此一介入措施對於減少後續發生中風之效益卻甚少被提及。如何於民眾運用前述以族群為基礎之初段預防措施,結合以個人高血壓進展風險分數為導向之篩檢與預防性投藥之次段預防措施,在現有之研究仍付之闕如。本論文因此希望能針對前述對結合初段與次段預防之中風防治措施所能預防中風發生的比例、介入後所增加之人年,以及調整生活品質後進行成本效益分析。
<研究目的> (1) 以具不同危險因子之社區世代為基礎,預測其多階段多因子高血壓進展及後續中風發生; (2) 利用(1),進一步發展個人化高血壓防治措施在中風防治的介入分析模型; (3) 評估彰化社區世代個人化高血壓防治措施之成本效益分析。 <材料與方法> 我們採用以基隆社區世代所發展的多階段多因子高血壓預測模式,配合不同血壓階段的中風發生率,套用於彰化社區世代具不同危險因子的族群。以馬可夫決策模型,考量中風後功能狀態,進行個人化高血壓防治相對於控制組之成本效益分析,並以機率性成本效益分析處理參數不確定性問題。主要結果呈現包括中風的減少、生活品質調整人年的增加,及增加成本效用比,並以成本效益散佈圖及接受曲線呈現。 <結果> 以彰化社區世代個人的危險因子進行的模擬分析,預測其中風的年發生率約為每千人年13例,包括3.59及9.48例的出血性和缺血性中風,個人化高血壓防治策略可降低17%中風發生(95%信賴區間:15-18%)。考慮中風的減少及其後續殘障等級的變化之後,個人化高血壓防治策略對個人平均可增加0.17個生活品質調整人年,且平均每人整體花費較控制組減少新台幣161,170元。在考量參數的變異之下,個人化高血壓防治策略的成本效益優勢仍然存在。 <結論> 本研究建立評估個人化高血壓及中風防治的架構,在考量高血壓狀態的動態轉移之下,對以全民為基礎的初段預防及高危險群者之預防性投藥及次段預防措施進行評估,結果發現個人化高血壓防治就成本效益的角度而言是一項節省成本的優勢策略,除了可增加生活品質調整人年之外,累積花費成本亦較低。本研究的結果預期可以做為個人化高血壓防治策略之參考。 | zh_TW |
dc.description.abstract | <Background> Although the control for hypertension have widely been accepted as a necessary component for stoke prevention, the heterogeneity regarding the evolution of hypertension in associated with the occurrence of stoke render the elucidation of the effectiveness of each components of prevention strategies intractable. As the primary prevention have gained great attention in current strategies of hypertension management, its contribution to stoke prevention remain not fully addressed. The effectiveness on the application of multiple prevention strategies including the population-based primary prevention and risk-oriented carotid ultrasound screening followed by a series of treatment and therapy for stoke prevention also has not been elaborated. The cost incurred by the multi-step prevention strategies and the attributes of its effectiveness including stroke averted, life-year gained, and quality adjusted life-years gained motivate our research by applying a cost-effectiveness analysis to evaluate the decision on the proposed personalized stroke prevention strategies.
<Aims> This thesis aims (1) to explore the dynamic of stoke embedded in the evolution of hypertension defined by multiple disease status including normal, prehypertension, stage I hypertension, and stage II hypertension; (2) to develop a risk-guided individual-tailored stoke prevention strategy incorporating primary and secondary prevention based on (1); and (3) to assess the cost-effectiveness of (2) applied to Changhua population following the principle of decision analysis. <Materials and Methods> We calculated the personalized risk score with 4-state hypertension Markov model underpinning in light of definition from JNC 7, normal, pre-hypertension, stage 1 hypertension, stage 2 hypertension. The clinical weights of the risk score were borrowed from literature with Keelung Community-based Screening (KCIS) cohort, and applied to the Changhua Community-based Screening (CHCIS) cohort to stratify the cohort into different risk groups. A Markov decision tree, incorporating the 4-state hypertension model, hemorrhagic stroke, ischemic stroke, three functional outcomes after stroke, and death was built. Finally, the probabilistic cost-effectiveness analysis of personalized prevention of hypertension compared with control group was conducted. The main outcome measures include stroke avoided and quality-adjusted life-year prolonged, incremental cost-utility ratio, and the acceptability curve for personalized prevention against control. <Results> Among the Changhua population, the incidence of stroke is 16 per 1,000 with 4.2 and 11.8 per 1,000 for hemorrhagic and ischemic type, respectively. The personalized prevention strategy results in stroke risk reduction by 17% (95% CI: 15-18%). Taking into account the stroke events reduction and the functional status after stroke, the personalized prevention program not only results in 0.17 QALY gained per person in a 20-year time horizon, but also leads to an average NTD 161,170 less expenditure per person. Considering the distribution of parameters, the benefit of personalized prevention program over control is still dominant even under the worst case of parameters. <Conclusion> We developed a framework for the evaluation of individual-tailored hypertension and stroke prevention, which incorporated primary and secondary prevention. As the personalized prevention is cost-effective against control in terms of quality-adjusted life year gained, our results support the personalized prevention as a promising policy for hypertension associated stroke. | en |
dc.description.provenance | Made available in DSpace on 2021-05-11T04:50:25Z (GMT). No. of bitstreams: 1 ntu-108-P06849005-1.pdf: 1221463 bytes, checksum: 2e314c9ffb936b41e7688b48935d98dd (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | Chapter 1. Introduction
1.1 The importance of hypertension prevention...1 1.2 Relationship between hypertension and stroke...2 1.3 Personalized hypertension prevention strategy...2 1.4 Cost-effectiveness analysis of hypertension associated with stroke...3 Chapter 2. Literature review 2.1 Stages of hypertension...6 2.2 Risk score of hypertension progression...7 2.3 Quality of life after stroke...13 2.4 Modified Rankin Scale (mRS)...14 2.5 Applying modified Rankin Scale to quality of life analysis...15 2.6 Modified Rankin scale distribution after stroke...16 Chapter 3. Materials and Methods 3.1 Study Design...21 3.2 Study population...22 3.3 Four-state Markov model of hypertension considering personal risk profiles...23 3.4 Incidence of stroke...27 3.5 Time-variant transition probability of the functional outcome after stroke...28 3.6 Utility of the functional outcome after stroke...29 3.7 Mortality of patients with and without stroke...30 3.8 Personalized intervention to prevent stroke...31 3.9 The cost of stroke...36 3.10 Markov decision tree...37 3.11 Cost-effectiveness Analysis...42 Chapter 4 Results 4.1 Personalized risk profiles in the CHCIS cohort...53 4.2 Incidence of stroke...55 4.3 Annual transition probability of functional states depending on time...56 4.4 Mortality of subjects with and without stroke...57 4.5 Cost-effectiveness of personalized prevention of hypertension...58 Chapter 5 Discussion...79 References...84 | |
dc.language.iso | zh-TW | |
dc.title | 中風相關的個人化高血壓預防之成本效益分析 | zh_TW |
dc.title | Cost-effectiveness analysis of personalized prevention for hypertension associated with stroke | en |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳祈玲,潘信良 | |
dc.subject.keyword | 高血壓,中風,馬可夫決策模型,成本效益分析, | zh_TW |
dc.subject.keyword | hypertension,stroke,Markov decision model,cost-effectiveness analysis, | en |
dc.relation.page | 87 | |
dc.identifier.doi | 10.6342/NTU201903838 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2019-08-16 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf | 1.19 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。